T-1101 tosylate NEW
| Price | $59 | $94 | $155 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-09-22 |
Product Details
| Product Name: T-1101 tosylate | CAS No.: 2250404-95-4 |
| Purity: 98.10% | Supply Ability: 10g |
| Release date: 2025/09/22 |
Product Introduction
Bioactivity
| Name | T-1101 tosylate |
| Description | T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 inhibitor with antitumor activity. |
| Animal Research | SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts. Dosage:25 mg/kg, 50 mg/kg. Oral administration; twice per day; 28 days |
| In vitro | T-1101 has good oral absorption, along with potent in?vitro antiproliferative activity (IC50: 14.8-21.5?nM). |
| In vivo | T-1101 tosylate can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 11 mg/mL (16.52 mM), Sonication is recommended. |
| Keywords | TAI-95 Tosylate | TAI95 Tosylate | TAI-95 | TAI95 | TAI 95 Tosylate | TAI 95 | T-1101 Tosylate | T1101 tosylate | T1101 Tosylate | T-1101 | T1101 | T 1101 Tosylate | T 1101 tosylate | T 1101 | PPI | MicrotubuleAssociated | Microtubule Associated | Inhibitor | inhibit | Hec1/Nek2 | Hec1 | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5.00/1KG |
VIP1Y
|
Wuhan JiyunZen Tech Co., Ltd.
|
2025-06-06 | |
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-30 | |
| $50.00/10g |
VIP3Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2023-08-14 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY